Background Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease worldwide. The increasing prevalence of NAFLD mirrors that of obesity and type 2 …

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in
western countries, affecting 25–30% of the general population and up to 65% in those with …

Background and aims Fatty liver diseases are highly prevalent in patients with coronary
artery disease (CAD) and might progress to irreversible liver fibrosis. Whether baseline liver …

ABSTRACT Background and Aims Metabolic dysfunction-associated steatotic liver disease
(MASLD) is often overlooked in patients with type 1 diabetes mellitus (T1DM). Our study …

Understanding the mechanisms linking steatosis to fibrosis is needed to establish a
promising therapy against nonalcoholic fatty liver disease (NAFLD). The aim of this study …

Autoimmune destruction of pancreatic β-cells results in the permanent loss of insulin
production in type 1 diabetes (T1D). The daily necessity to inject exogenous insulin to treat …

Background The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing
among patients with type 1 diabetes (T1D) paralleling the increasing prevalence of obesity …

Diabetic neuropathy (DN) is one of most disabling disorder complicating diabetes mellites
(DM), which affects more than 50% of the all diabetic patients during the disease course …

Background The aim of this study is to evaluate the performance of three existing prediction
scores which are applicable to adults for identifying nonalcoholic fatty liver disease (NAFLD) …

Identification of biomarkers associated with protection from developing diabetic
complications is a prerequisite for an effective prevention and treatment. The aim of the …